Amy Jo Chien
Impact in
- Cancer Research top 1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
Papers in
-
- Breast Cancer Treatment Studies 24
- Cancer Genomics and Diagnostics 8
- Oncology 37
- HER2/EGFR in Cancer Research 18
- Cancer Treatment and Pharmacology 8
- Co-authors
- Michelle Melisko (25 shared papers)Hope S. Rugo (27 shared papers)Mitchell P. Rosen (6 shared papers)Joseph M. Letourneau (5 shared papers)Marcelle Ivonne Cedars (5 shared papers)Patricia Katz (2 shared papers)Erin E. Ebbel (2 shared papers)Mark M. Moasser (8 shared papers)
- Journals
- Breast Cancer Research and Treatment (19 papers)npj Breast Cancer (12 papers)JAMA Oncology (5 papers)Clinical Cancer Research (5 papers)Journal of Clinical Oncology (5 papers)
- Partner nations
- United StatesAustraliaSpain
In The Last Decade
Amy Jo Chien
88 papers receiving 5.8k citations
Amy Jo Chien's Hit Papers
Peers
Comparison fields: 5 of 116
- Cancer Research 1.6k
- Oncology 2.6k
- Reproductive Medicine 329
- Pulmonary and Respiratory Medicine 1.1k
- Public Health, Environmental and Occupational Health 723
Countries citing papers authored by Amy Jo Chien
This map shows the geographic impact of Amy Jo Chien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Jo Chien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Jo Chien more than expected).
Fields of papers citing papers by Amy Jo Chien
This network shows the impact of papers produced by Amy Jo Chien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Jo Chien. The network helps show where Amy Jo Chien may publish in the future.
Co-authors
The 25 scholars most cited alongside Amy Jo Chien, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 90 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer Hit paper breakdown → | 2020 | 579 |
| 2 | Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer Hit paper breakdown → | 2016 | 468 |
| 3 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 461 |
| 4 | Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer Hit paper breakdown → | 2011 | 454 |
| 5 | Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial Hit paper breakdown → | 2020 | 428 |
| 6 | 2020 | 355 | |
| 7 | Adaptive Randomization of Neratinib in Early Breast Cancer Hit paper breakdown → | 2016 | 302 |
| 8 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial Hit paper breakdown → | 2021 | 258 |
| 9 | 2011 | 180 | |
| 10 | 2020 | 169 | |
| 11 | 2020 | 137 | |
| 12 | Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy Hit paper breakdown → | 2023 | 137 |
| 13 | Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases Hit paper breakdown → | 2022 | 136 |
| 14 | 2016 | 117 | |
| 15 | 2006 | 100 | |
| 16 | 2020 | 96 | |
| 17 | 2020 | 80 | |
| 18 | 2021 | 80 | |
| 19 | 2015 | 75 | |
| 20 | 2017 | 71 |
About Amy Jo Chien
Amy Jo Chien is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging, having authored 90 papers that have together received 5.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (24 papers), HER2/EGFR in Cancer Research (18 papers), Cancer Genomics and Diagnostics (8 papers), Cancer Treatment and Pharmacology (8 papers), Reproductive Biology and Fertility (8 papers), Advanced Breast Cancer Therapies (6 papers), Breast Lesions and Carcinomas (4 papers) and Brain Metastases and Treatment (4 papers). The work is most often cited by research in Cancer Research (1.6k citations), Oncology (2.6k citations), Reproductive Medicine (329 citations), Pulmonary and Respiratory Medicine (1.1k citations) and Public Health, Environmental and Occupational Health (723 citations). Amy Jo Chien has collaborated with scholars based in United States, Australia and Spain. Frequent co-authors include Michelle Melisko, Hope S. Rugo, Mitchell P. Rosen, Joseph M. Letourneau, Marcelle Ivonne Cedars, Patricia Katz, Erin E. Ebbel, Mark M. Moasser, Audra Katz and Paul Edward Goss. Their work appears in journals such as Breast Cancer Research and Treatment, npj Breast Cancer, JAMA Oncology, Clinical Cancer Research and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.